4.2 Review

New perspectives for the treatment options in spinal cord injury

Journal

EXPERT OPINION ON PHARMACOTHERAPY
Volume 9, Issue 16, Pages 2773-2800

Publisher

TAYLOR & FRANCIS LTD
DOI: 10.1517/14656566.9.16.2773

Keywords

blood-spinal cord barrier; edema formation; electrophysiology; endothelial cells; functional paralysis; glial cells; motor neuron; spinal cord injury; spinal cord pathology; treatment

Funding

  1. Swedish Medical Research Council [2710,]
  2. Goran Gustafison Foundation, Stockholm, Sweden
  3. Astra-Zeneca, Molndal, Sweden
  4. Acure Pharma, Uppsala, Sweden
  5. Alexander von Humboldt Foundation, Bonn, Germany
  6. Global College of Neuroprotection and Neuroregeneration (GCNN), London, UK
  7. IPSEN Beufour, Paris, France
  8. Ebewe Pharma, Austria
  9. Department of Science Technology
  10. Government of India, University Grants Commission, New Delhi, India
  11. Indian Medical Research Council, New Delhi, India

Ask authors/readers for more resources

Spinal cord injury (SCI) is a serious clinical disorder that leads to lifetime disability for which no suitable therapeutic agents are available so far. Further research is needed to understand the basic mechanisms of spinal cord pathology that results in permanent disability and poses a heavy burden on our society. In the past, a lot of effort was placed on improving functional outcome with the help of various therapeutic agents, however less attention has been paid on the development and propagation of spinal cord pathology over time. Thus, it is still unclear whether improvement of functional outcome is related to spinal cord pathology or vice versa. Few drugs are able to influence functional outcome without having any improvement on cord pathology. Some drugs, however, can lessen cord pathology but fail to influence the functional outcome. The goal of future treatment options for SCI is therefore to find suitable new drugs or a combination of existing drugs and to use various cellular transplants, neurotrophic factors, myelin-inhibiting factors, tissue engineering and nano-drug delivery to improve both the functional and the pathological outcome in the inured patient. This review deals with the key aspects of the latest treatments for SO and suggests some possible future therapeutic measures to enhance healthcare in clinical situations.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available